<td>We registered for iGEM then had a great summer time. We are now waiting to attend the Giant Jamboree.</td>

<td>We plan to make the competition deliverables met on time.</td>

<td>We completed the <a href="https://2018.igem.org/Team:Pasteur_Paris/Attributions" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">attributions </a> page on our wiki.</td>

<td>We successfully completed the <a href="https://2018.igem.org/Team:Pasteur_Paris/InterLab" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">InterLab </a> Measurement Study.</td>

<td>We created a new BioBrick part as expected : <a href="http://parts.igem.org/Part:BBa_K2616000" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">BBa_K2616000</a>. This part permits to express pro-NGF and secrete it in the extracellular medium using E. coli type I secretion system. We used inducible promoter T7, in order to control pro-NGF production thanks to IPTG induction. We also added an His-tag in N-terminal in order to purify it. pro-NGF is addressed to Type I Secretion System by fusing to it the the 60 C-terminal aminoacide of alpha-haemolysin HlyA. Since the export peptide is not processed when passing through the secretion pore, we separated pro-NGF from this 60 aminoacid long sequence by a cleaving site for TEV protease Nter-ENLYFQ-Cter. This part also permits to secrete TEV protease, under the same promoter, via this same secretion system. We succeeded in characterizing our pro-NGF by sequencing and mass spectrometry but could not purify it from the media. </td>

We hosted the <a href="https://2018.igem.org/Team:Pasteur_Paris/Collaborations#MeetUp"style="font-weight: bold ; color:black; text-decoration:none;" target="_blank">4th Parisian Meet-Up </a>where we organized a Tiny Jamboree in the morning in order to practice with all the French teams for the Giant. We also organized and attended round tables about bioethics with multiples professionals during the afternoon.</br>

We collaborated with other iGEM teams for the Interlab (Sorbonne U Paris), by sharing and testing protocols (WPI Worcester) as well as other non-scientific collaborations. You can read about them on this <a href="https://2018.igem.org/Team:Pasteur_Paris/Collaborations" style="font-weight: bold ; color:black; text-decoration:none;" target="_blank"> page </a>.</br>

We took into account the advices of many professionals in the conception and confinement of our interface NeuronArch. Our juridic team has worked with the Ethic Committeeof the Institut Pasteur on the ethic and safety issues surrounding the use of GMOs inside the human body and try to destigmatize the use of GMOs to the general public. Because we also thought about the consequence of a possible release of our GMOs in the environnement, we also integrated a thermosensitive Kill-Switch inside our bacteria. You can read about it on this page. </br>

<td>Integrated HP</td>

We thought with care of every aspect of our project by interviewing many experts of their fields (biofilms, infections, microfluidic and prosthesis) but also associations for the right of amputees as well as surgeons and took into account their advices in our final biological interface as well as our prototype.</tr>

<td>

<td>We modeled how NGF is produced in our modified <i> E. Coli </i>, its diffusion in a medium environment and its consequences on neurons growth.  It helped to have an insight on which concentration of NGF to use in our experiments and also helped in predicting the futur growth of nerves inside of prototype. The mechanical model presents tools to visualize constraints on the humerus and the femur and was suggested to a researcher </td>